Balance Sheet
Cash Flow Statement
AmortizationAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Ascendis Pharma A (ASND) over the last 12 years, with Q4 2025 value amounting to -$431899.4.

  • Ascendis Pharma A's Gains from Investment Securities rose 8108.68% to -$431899.4 in Q4 2025 from the same period last year, while for Dec 2025 it was -$7.6 million, marking a year-over-year decrease of 2913.23%. This contributed to the annual value of -$7.5 million for FY2025, which is 2814.65% down from last year.
  • Latest data reveals that Ascendis Pharma A reported Gains from Investment Securities of -$431899.4 as of Q4 2025, which was up 8108.68% from -$2.5 million recorded in Q3 2025.
  • In the past 5 years, Ascendis Pharma A's Gains from Investment Securities ranged from a high of $1.6 million in Q4 2022 and a low of -$4.6 million during Q2 2025
  • Moreover, its 5-year median value for Gains from Investment Securities was -$247004.0 (2022), whereas its average is -$875288.5.
  • Per our database at Business Quant, Ascendis Pharma A's Gains from Investment Securities surged by 28257.51% in 2022 and then crashed by 137809.6% in 2025.
  • Ascendis Pharma A's Gains from Investment Securities (Quarter) stood at $410685.6 in 2021, then surged by 282.58% to $1.6 million in 2022, then plummeted by 314.34% to -$3.4 million in 2023, then surged by 32.19% to -$2.3 million in 2024, then surged by 81.09% to -$431899.4 in 2025.
  • Its Gains from Investment Securities stands at -$431899.4 for Q4 2025, versus -$2.5 million for Q3 2025 and -$4.6 million for Q2 2025.